125 related articles for article (PubMed ID: 38185266)
1. Chemotherapy for a secondary malignancy nearly restores complete chimerism in an SCID-patient after HSCT.
Maier FI; Schulz A; Furlan I; Felgentreff K; Jacobsen EM; Sirin M; Schwarz K; Pannicke U; Stursberg J; Debatin KM; Hönig M
Clin Immunol; 2024 Feb; 259():109891. PubMed ID: 38185266
[TBL] [Abstract][Full Text] [Related]
2. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.
Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F
Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161
[TBL] [Abstract][Full Text] [Related]
3. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity.
Fitch T; Lane A; McDonnell J; Bleesing J; Jordan M; Kumar A; Khandelwal P; Khoury R; Marsh R; Chandra S
Transplant Cell Ther; 2024 Jan; 30(1):101.e1-101.e12. PubMed ID: 37821080
[TBL] [Abstract][Full Text] [Related]
4. CD3
Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
[TBL] [Abstract][Full Text] [Related]
5. Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood.
Day JW; Elfeky R; Nicholson B; Goodman R; Pearce R; Fox TA; Worth A; Booth C; Veys P; Carpenter B; Hough R; Gaspar HB; Titman P; Ridout D; Workman S; Hernandes F; Sandford K; Laurence A; Campbell M; Burns SO; Morris EC
J Clin Immunol; 2022 Aug; 42(6):1230-1243. PubMed ID: 35579633
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
9. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.
Koreth J; Kim HT; Nikiforow S; Milford EL; Armand P; Cutler C; Glotzbecker B; Ho VT; Antin JH; Soiffer RJ; Ritz J; Alyea EP
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1516-21. PubMed ID: 24907627
[TBL] [Abstract][Full Text] [Related]
10. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z
Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720
[No Abstract] [Full Text] [Related]
11. [Establishment of Mouse Model of H-2 Haploidentical Hematopoietic Stem Cell Transplantation from Double Donors].
Wang XN; Liang YM; Deng L; Wang L; Wang Y; Huang YJ; Liu TQ; Zuo HL; Hu KX; Qiao JH; Sun QY; Guo M; Ai HS; Yu CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):522-529. PubMed ID: 28446305
[TBL] [Abstract][Full Text] [Related]
12. Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation: is it clinically relevant?
Miura Y; Yoshioka S; Yao H; Takaori-Kondo A; Maekawa T; Ichinohe T
Chimerism; 2013; 4(3):78-83. PubMed ID: 23880502
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
14. The study of engraftment after hematopoietic stem cell transplantation: From the presence of mixed chimerism to the development of immunological tolerance.
Andreani M; Gregori S
HLA; 2018 Dec; 92 Suppl 2():57-59. PubMed ID: 30270557
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Second Allogeneic HSCT for Patients with Inborn Errors of Immunity: Retrospective Study of 20 Years' Experience.
Mehta P; Tsilifis C; Lum SH; Slatter MA; Hambleton S; Owens S; Williams E; Flood T; Gennery AR; Nademi Z
J Clin Immunol; 2023 Nov; 43(8):1812-1826. PubMed ID: 37452206
[TBL] [Abstract][Full Text] [Related]
16. Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study.
Ishiyama K; Takami A; Suzuki S; Konaka H; Namiki M; Ooi A; Nakao S
Jpn J Clin Oncol; 2009 Dec; 39(12):807-12. PubMed ID: 19770130
[TBL] [Abstract][Full Text] [Related]
17. Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases.
Umeda K; Adachi S; Tanaka S; Miki M; Okada K; Hashii Y; Inoue M; Cho Y; Koh K; Goto H; Kajiwara R; Hyakuna N; Kato K; Morio T; Yabe H;
Pediatr Blood Cancer; 2016 Dec; 63(12):2221-2229. PubMed ID: 27554591
[TBL] [Abstract][Full Text] [Related]
18. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
Maris M; Storb R
Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases.
Faraci M; Bagnasco F; Leoni M; Giardino S; Terranova P; Subissi L; Di Duca M; Di Martino D; Lanino E
Biol Blood Marrow Transplant; 2018 May; 24(5):1088-1093. PubMed ID: 29292059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
